Vitamin C Deficiency
Conditions
Keywords
vitamin C, quality of life, terminal cancer
Brief summary
This study determines whether high dose vitamin C is effective for quality of life in terminal cancer patients.
Detailed description
The investigator's project is a single medical center, randomized double- blinded trial. The target group is terminal cancer patients at Palliative care clinics. The experimental group will receive intravenous high-dose vitamin C 30 g in 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment. The control group will receive 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment. The primary outcome is the improvement of quality of life, measured by European Organization for Research and Treatment of cancer (EORTC). The secondary outcome is the survival analysis.The participants will be followed up weekly for 2 weeks, then bi-weekly for 6 months.
Interventions
DRUGhigh-dose vitamin C 30gm
High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.
OTHERnormal saline
500ml normal saline, once per week, and total 4-week treatment
Sponsors
National Taiwan University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Masking description
double-blinded
Intervention model description
Parallel Assignment Randomized double-blinded controlled trial
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
-Terminal colon cancer patients without pleural effusions, who will not receive any curative radiotherapy or chemotherapy.
Exclusion criteria
* Renal metastasis or obstructive uropathy by radiology * Nephrotic syndrome * Creatinine over 1.5mg/dl * Urolithasis * Under other folk therapy or vitamin infusion therapy * Those who can't exercise the right of consent * Those who can't answer the questionaires * Glucose-6-Phosphate Dehydrogenase Deficiency * Severe lower leg edema or general edema
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The improvement of quality of life (QOL) | 6 months | QOL measured by European Organization for Research and Treatment of cancer Quality of Life Questionnaire (EORTC QLQ)-C30 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival analysis | 6 months | death time of those who have completed the 4-week intervention |
Countries
Taiwan
Contacts
Primary ContactChin-Ying Chen, MD, MHSc
Outcome results
None listed